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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Emerging non-7-valent pneumococcal conjugate vaccine (PCV7) sero-
types have replaced PCV7 serotypes in childhood invasive pneumococcal disease (IPD). This
study was designed to describe the IPD caused by non-PCV7 serotypes under partial PCV7 im-
munization in Taiwan.
Methods: All children <18 years of age diagnosed with IPD at National Cheng Kung University
Hospital from 1998 to 2010 were enrolled. Clinical and laboratory information was collected.
Pneumococcal isolates were tested for antimicrobial susceptibility and interpreted using Clin-
ical Laboratory Standard Institute guidelines (2008). Serotypes were determined using the
capsular swelling method.
Results: One hundred and five patients with IPD were identified, including 75 PCV7 and 30
non-PCV7 isolates. Pneumonia (63.3%) was the leading clinical manifestation of non-PCV7
IPDs and 78.9% of pneumonia cases were associated with necrotizing pneumonia or empyema.of Pediatrics, College of Medicine, National Cheng Kung University and Hospital, 138, Sheng Li Road,
du.tw (C.-C. Liu).
ight ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
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562 C.-F. Shen et al.Children with non-PCV7 IPDs had longer febrile days, required longer intensive care unit
stays, and had a higher C-reactive protein level than those with PCV7 IPDs (p < 0.05).
Serotype 3 is the most common non-PCV7 serotype (46.7%) and possesses the highest
potential for pulmonary complications (p < 0.05, odds ratio: 0.114; 95% confidence interval,
0.013 e 0.973).
Conclusion: The changing epidemiology of IPDs following the introduction of PCV7 has been
noted. Expanded serotype coverage of the vaccine is warranted.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Streptococcus pneumoniae remains one of the most
common pathogens in pediatric infectious diseases
causing bacteremia, pneumonia, meningitis, and perito-
nitis. The development of a conjugate pneumococcal
vaccine had made immunization possible in children aged
<2 years.1 The 7-valent pneumococcal conjugate vaccine,
PCV7, (Prevnar; Pfizer Inc., Philadelphia, PA, USA) which
includes serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F
covered 80% of invasive pneumococcal diseases (IPDs) in
the Unites States in 1998.2 The introduction of PCV7
among the routine childhood vaccinations decreased the
incidence of IPD and also produced a significant reduction
in pneumococcal disease in unvaccinated children.3,4
Along with the widespread use of PCV7, IPDs caused by
nonvaccine serotypes had been increasingly reported in
the United States and Europe.3,5 Among these emerging
non-PCV7 serotypes, serotype 19A had been notorious for
its high prevalence and penicillin non-susceptibility.6
Other serotypes, such as serotype 15 and 33 were also
increasing in the United States.7 In addition, the clinical
manifestations of IPD were also affected along with the
change of serotype epidemiology. The increasing propor-
tion of IPD caused by non-PCV7 serotypes had dominated
the overall disease manifestations. Among these, pneu-
mococcal parapneumonic empyema (PPE) is becoming the
most common clinical presentation of IPD in the post-
vaccine era. Serotypes 1 and 3 are the leading serotypes
responsible for PPE in many areas.8,9 It could not be
emphasized more that IPDs caused by non-PCV7 serotypes
have become a current challenge in the postvaccine
period.5,7,9,10
Children hospitalized with pneumococcal community
acquired pneumonia are common in Taiwan prior to the
introduction of PCV7 on October. 2005.11 PCV7 was not
added into the routine immunization program until now.
Only 15.9% of children <5 years of age received one or
more doses of PCV7 in 2007.10 In Taiwan, the pneumo-
coccal vaccine coverage rate is low. Whether serotype
replacement following the introduction of PCV7 will occur
in Taiwan is uncertain and needs to be monitored. Ac-
cording to a national surveillance study conducted in 2007
in Taiwan, PCV7 covered only 60e70% of IPDs in children
<5 years of age, which was lower than in the Unites
States.10 This implies that a large portion of IPDs were
caused by non-PCV7 serotypes in Taiwan. Therefore, the
aims of the present study are to describe the epidemiology
and clinical manifestation of IPD caused by non-PCV7serotypes and compare with PCV7 serotypes prior to and
after the introduction of the vaccine.Materials and methods
Patients and case definition
All children <18 years old who were diagnosed with IPD
from February 1998 to February 2010 at National Cheng
Kung University Hospital, a 1200-bed, tertiary care medical
center in southern Taiwan, were enrolled. Demographic
information, past history, clinical and laboratory findings,
hospital course, therapeutic regimens, and outcome were
obtained from the medical records. IPD includes bacter-
emia, pneumonia, meningitis, peritonitis, and bone and
joint infections. IPD is defined by the isolation of pneu-
mococci from normally sterile sites, such as blood, cere-
brospinal fluid, pleural effusion, ascites, and synovial fluid.
Radiological images and pleural effusion data were
reviewed in pneumonia cases. The characteristics of
pleural effusions were based on Light’s criteria for empy-
ema. Complicated pneumonia was defined by the presence
of pulmonary complications, such as empyema, pneuma-
tocele, or lung abscesses.Bacterial susceptibility and serotyping
The pneumococcal isolates were reconfirmed with optochin
sensitivity and bile solubility tests after isolation. Isolates
were harvested immediately after identification and stor-
age in preservative medium at 70C. These isolates were
then thawed to room temperature and inoculated on 5%
sheep blood agar to identify typical colony morphology.
Then they were tested for penicillin and ceftriaxone sus-
ceptibility using the agar dilution method and were inter-
preted by Clinical Laboratory Standard Institute guidelines
(2008). The penicillin susceptibility values were as follows:
susceptible, minimal inhibitory concentration (MIC)
0.06 mg/mL; resistant, MIC 0.12 mg/mL in meningitis
criteria; susceptible, MIC 2 mg/mL; and resistant, MIC
8 mg/mL in non-meningitis criteria. The ceftriaxone sus-
ceptibility values were as follows: susceptible, MIC
0.5 mg/mL; resistant, MIC 2 mg/mL in meningitis criteria;
susceptible, MIC 1 mg/mL; resistant, MIC 4 mg/mL in non-
meningitis criteria. The serotypes were determined using
the capsular swelling method (Quellung reaction).
Serotype manifestations of invasive pneumococcal disease 563Statistical analysis
Continuous variables were analyzed by Student t test and
presented as the mean and standard deviation. Categorical
variables were analyzed by the Pearson’s Chi-square test
and presented with proportion. A p value <0.05 was
considered to be statistically significant.Results
IPD was identified in 105 patients, which included 75 PCV7
and 30 non-PCV7 isolates. Fig. 1 shows the seasonal distri-
bution of IPD cases according to age. Incidence of IPD was
highest from November to April. Table 1 shows the de-
mographic and clinical characteristics of the 105 cases with
IPD. Themean agewas 3.7 years (range: 0.3e14.4 years) and
the female to male ratio was 1.3. Twenty-four patients
(22.9%) had underlying diseases, including seven with ma-
lignancy or hematological disorders, four with genetic dis-
orders, six with nephrotic syndrome, one with congenital
heart disease, one with biliary atresia, and one with idio-
pathic chronic diarrhea. Age, gender, previous pneumo-
coccal vaccination, and pre-existing underlying disease did
not differ between children with PCV7 or non-PCV7 serotype
infections. Only three cases had had a prior 23-valent
pneumococcal polysaccharide vaccination. Nearly 20% of
IPD cases presented with hemodynamic instability (21.8%) or
respiratory failure (18.8%). However, childrenwith non-PCV7
serotype infection had longer febrile days (9.6 5.5 days vs.
7.0  6.0 days, p Z 0.015) and more need for an intensive
careunit (ICU) stay (69%vs. 41.4%,pZ0.013) than thosewith
PCV7 serotype infection. However, the length of hospitali-
zation and ICU days did not differ between these two groups.
More complicated pneumonia was found in the non-PCV7
group (78.9%) than in the PCV7 group (55.1%), but this dif-
ference was not statistically significant. Four fatal cases
were infected with PCV7 serotypes (two with serotype 14,
onewith serotype 19F, and onewith serotype 9V); three fatal
cases were infected with non-PCV7 serotypes (one with
serotype 11A, one with serotype 3, and one with serotype
19A). All fatal cases had concurrent bacteremia. Overall, the
case-fatality rate was 6.7%.Figure 1 Seasonal distribution of invasive pneumococcal
disease cases according to age from 1998 to 2010.Table 2 lists clinical manifestations of PCV7 and non-
PCV7 serotype infection according to age. Overall, pneu-
monia/empyema (45.7%) was the leading cause of all IPDs.
However, children with PCV7 infection were most likely to
present with bacteremia than those with non-PCV7 infec-
tion (44% vs. 20%, p < 0.05). Other sites of infections
included one case of septic arthritis (PCV7 serotype), one
case of mastoiditis (PCV7 serotype), and five cases of
spontaneous peritonitis (four PCV7 serotypes and one non-
PCV7 serotype).
The number of IPD cases varied year by year. During the
first 2 years following the introduction of PCV7, the IPD
increased from six cases in 2005 to 12 cases in 2007. But the
IPD trend seemed to decline gradually over the next 3 years
(Fig. 2). The percentage of IPD caused by PCV7 serotypes
declined from 77.6% during the 1998-2005 period to 55.2%
during the 2006-2010 period. By contrast, IPD caused by
non-PCV7 coverage serotypes increased from 22.4% during
1998-2005 period to 44.8% during 2006-2010 period
(p < 0.05).
Table 3 shows that the percentage of pneumococcal
serotypes was different among different age groups. Sero-
type 14 was the most common serotype among PCV7 IPDs,
followed by serotypes 6B, 23F, and 19F. Serotype 3 was the
leading cause of non-PCV7 IPDs, and was the fourth com-
mon serotypes among all IPD cases. Serotype 3 accounted
for 10.5% of IPDs during the 1998e2005 period but
increased to 20.7% during the 2006e2010 period (data not
shown). Serotype 6B is the leading cause of IPD in children
aged <2 years and >5 years old. Serotype 14 was more
common in children aged 2e5 years. The PCV7 covered
76.7% of isolates in children aged <2 years, 71.7% in chil-
dren aged 2e5 years, and 63.3% in children aged >5 years.
The overall coverage rate for PCV7 in children was 71.4%.
The coverage rate increased to 92.4% for 13-valent pneu-
mococcal vaccine (ranging from 86.4% in children aged >5
years to 96.2% in children aged between 2 years and 5
years).
Leukocytosis with the presence of immature poly-
morphonuclear leukocytes (PMN), and marked elevated C-
reactive protein (CRP) were common laboratory findings in
both groups (Table 4). Children with non-PCV7 IPDs had a
higher CRP level (212.0  124.4 mg/L) than those with PCV7
IPDs (150.2  119.6 mg/L, p < 0.05). Both PCV7 and non-
PCV7 isolates demonstrated an antimicrobial susceptibility
of >90% to penicillin and ceftriaxone using non-meningitis
criteria. Nearly all pneumococcal isolates were suscepti-
ble to penicillin using non-meningitis criteria except one,
serotype 19A. Serotype 19A had the lowest susceptibility to
penicillin (3/4, 75%) and ceftriaxone (1/4, 25%, p < 0.05)
using non-meningitis criteria. Using meningitis criteria,
PCV7 isolates had lower penicillin susceptibility (17.3%)
than non-PCV7 isolates (53.3%, p < 0.05). Serotype 3 had a
higher susceptibility to both penicillin (10/14, 71.4%) and
ceftriaxone (13/14, 92.9%) than other serotypes using
meningitis criteria (p < 0.05).
Table 5 shows the serotypes distribution of pulmonary
complications in cases with pneumonia. Serotype 14 is the
most common serotype in overall pneumonia, whereas
serotype 23F was more common in uncomplicated lobar
pneumonia. In comparison with uncomplicated lobar
pneumonia, serotype 3 was the major serotype of
Table 1 Demographic data and clinical outcomes of hospitalized children with invasive pneumococcal disease from 1998 to
2010 according to PCV7 and non-PCV7 serotypes.
Basic information PCV7 serotypes (n Z 75) Non-PCV7 serotypes (n Z 30) p
Age (y) 3.6  2.8 3.9  2.2 0.199
Male/female ratio 1.2 1.5 0.620
Underlying disease 18 (24.0) 6 (20) 0.661
Previous pneumococcal vaccinationa 2/72 (2.8) 1/29 (3.4) 1.000
Duration of hospitalization (d) 15.3  10.7 16.2  8.5 0.230
Total febrile days (d) 7.0  6.0 9.6  5.5 0.015
Requirement for ICU stay 29/70 (41.4) 20/29 (69.0) 0.013
Duration of ICU stay (d) 11.3  6.7 11.5  6.3 0.894
Hemodynamic instability 14/72 (19.4) 7/29 (24.1) 0.601
Respiratory failure 13/72 (18.1) 6/29 (20.7) 0.760
Complicated pneumonia 16/29 (55.2) 15/19 (78.9) 0.096
Mortality 4 (5.3) 3 (10.0) 1.000
Data are presented as n (%) or mean  SD unless otherwise indicated.
ICU Z intensive care unit; PCV7 Z 7-valent pneumococcal vaccine.
a 23-valent polysaccharide pneumococcal vaccine (PPV23).
564 C.-F. Shen et al.complicated pneumonia (odds ratio Z 0.114; 95% confi-
dence interval, 0.013 e 0.973). Children with serotype 3
pneumococcal pneumonia had longer febrile days
(13.4  7.4 days) and length of hospitalization (19.8  7.2
days) than those with non-serotype 3 pneumococcal pneu-
monia (9.2  6.8 days; 14.3  3.8 days, p < 0.05). In terms
of all IPD cases, serotype 3 infections are associated higher
CRP level (230.3  95.7 mg/L vs. 157.9  125.1 mg/L,
p < 0.05) and longer febrile days (11.9  5.2 days vs.
6.9  5.9 days, p < 0.05) than non-serotype 3 cases.Discussion
In this study, we showed the change of clinical manifesta-
tions and serotype distribution of IPD caused by PCV7 and
non-PCV7 serotypes after the introduction of PCV7. Bying-
ton et al9 has shown that even though the percentage of
IPDs has declined gradually after universal vaccination of
PCV7, the proportion of pneumonia, especially complicatedTable 2 Major clinical manifestations among hospitalized chil
according to PCV7 and non-PCV7 serotypes and age.
PCV7 serotypes
<2 y 2 y
Bacteremia alonea 12 (52.2) 21 (40.4)
Pneumoniaa,b 7 (30.4) 22 (42.3)
Meningitisc 2 (8.7) 5 (9.6)
Other manifestations d 2 (8.7) 4 (7.7)
Total 23 (100.0) 52 (100.0)
Data are presented as n (%).
PCV7 Z 7-valent pneumococcal vaccine.
a In all cases, PCV7 serotypes group vs. non-PCV7 serotypes group,
b In children aged 2 years, PCV7 serotypes group vs. non-PCV7 ser
c In non-PCV7 serotypes group, children <2 years old vs. children 
d Other manifestations: one case of septic arthritis and one case of
five cases are spontaneous peritonitis.pneumonia, has increased along with the emergence of
non-PCV7 serotypes.
Previous studies demonstrated that serotypes 14, 19F,
6B, 3, and 23F were the most common serotypes among
pediatric IPDs in Taiwan.10,12,13 Among these, only serotype
3 is not covered by PCV7. Although a significant decrease in
pediatric IPD occurred throughout the world after the
recent introduction of PCV7, the incidence of complicated
pneumonia, especially caused by the non-PCV7 serotypes,
is increasing.14,15 Children with non-PCV7 pneumococcal
infections had a more prolonged course of hospitalization
than those with PCV7 IPDs, in part because of the high rate
of complicated pneumonia. Those with complicated pneu-
monia needed more invasive procedures and longer days for
parenteral antimicrobial treatment to achieve defever-
ence. Among these non-PCV7 infections, serotype 3 plays
an important role in necrotizing pneumonia because of its
invasiveness in pulmonary infection.16 Indeed, from our
result, the reason why non-PCV7 IPD had higher CRP level
and more febrile days than PCV7 IPD could be explained bydren with invasive pneumococcal disease from 1998 to 2010
Non-PCV7 serotypes
Total <2 y 2 y Total
33 (44.0) 2 (28.6) 4 (17.4) 6 (20.0)
29 (38.7) 2 (28.6) 17 (74.0) 19 (63.4)
7 (9.3) 3 (42.8) 1 (4.3) 4 (13.3)
6 (8.0) 0 (0.0) 1 (4.3) 1 (3.3)
75 (100.0) 7 (100.0) 23 (100.0) 30 (100.0)
p < 0.05.
otypes group, p < 0.05.
2 years old, p < 0.05.
mastoiditis in children <2 years in PCV7 serotype; the remaining
Figure 2 Annual case number of invasive pneumococcal
disease among hospitalized children from 1998 to 2010 ac-
cording to PCV7 and non-PCV7 serotypes. PCV7 Z 7-valent
pneumococcal vaccine.
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monary complication. Meanwhile, not only serotype 3 could
cause complicated pneumonia, but also other serotypes,
such as, serotype 1 which accounted for the majority of
complicated pneumonia in the United States and the United
Kingdom.8,17 Pulmonary complication related to non-PCV7
serotypes is now an increasing problem worldwide.
The present study showed that serotype 3 S. pneumo-
niae had contributed to IPDs prior to the administration of
PCV7 and has become a significant problem in Taiwan
during the postvaccine era. Serotype 3 infection also occurs
in those aged >65 years.10 Serotype 3 can spread from
children to the elderly and cause invasive disease in bothTable 3 Distribution of serotypes and vaccine coverage rate am
from 1998 to 2010 according to age.
Serotype
<2 y (n Z 30)
PCV7 serotypes 14 4 (13.3)a
6B 9 (30.0)a
23F 6 (20.0)
19F 2 (6.7)
9V 2 (6.7)a
18C 0 (0.0)
4 0 (0.0)
Non-PCV7 serotype 3 4 (13.3)
6A 0 (0.0)
19A 0 (0.0)
10A 2 (6.7)
23A/B 0 (0.0)
11A 1 (3.3)
9A/L 0 (0.0)
9N 0 (0.0)
7-valent vaccine coverage rate 23 (76.7)
10-valent vaccine coverage ratec 23 (76.7)
13-valent vaccine coverage rated 27 (90.0)
Data are presented as n (%).
PCV7 Z 7-valent pneumococcal vaccine.
a Children aged <2 years old vs. children aged 2e5 years, p < 0.05
b Children aged 2e5 years vs. children aged >5 years, p < 0.05.
c 10-valent vaccine includes serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C,
d 13-valent vaccine includes serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14populations. Therefore, the need for vaccine coverage for
serotype 3 is an important issue. The 10-valent pneumo-
coccal conjugate protein (PCV10), which includes serotypes
1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F, was introduced
into Taiwan in 2010. Although some evidence demonstrated
that PCV10 produces cross protection against serotype 19A
by inducing opsonophagocytic activity, serotype 3 is still not
covered by PCV10.18
In the present study, none of the IPD cases had received
PCV7 vaccination. Only three patients had a 23-valent
polysaccharide pneumococcal (PPV23) vaccination at the
age of 2 years. Two cases developed breakthrough in-
fections (serotypes 6B and 14), and another had serotype
23A/B pneumococcal infection within the following 2 years
after vaccination. Butler et al19 showed the overall efficacy
of PPV23 was 57%, which also varied according to serotypes.
Moreover, the PPV23 efficacy did not decline over time
after vaccination. Therefore, two breakthrough IPDs in the
present study are more likely to result from suboptimal
vaccine efficacy. In fact, PCV7 had better vaccine efficacy
(76.8w 93.9%), enhanced immune response, and reduction
of pneumococcal carriage compared with PPV23.2023
Not only in children aged <24 months, but also catch-up
vaccination among children aged 24e59 months who
are unvaccinated were suggested universal PCV7
vaccination.1,24
Although the PCV7 coverage rate remains low in Taiwan,
Liao et al25 had demonstrated that the incidence of IPD still
declined after the introduction of PCV7. This might be due
to the decreased circulation of pathogens amongong hospitalized children with invasive pneumococcal disease
Common serotype by age group
2e5 y (n Z 53) >5 y (n Z 22) Total (n Z 105)
19 (35.8)b 2 (9.1) 25 (23.8)
6 (11.3) 5 (22.7) 20 (19.0)
9 (17.0) 2 (9.1) 17 (16.2)
3 (5.7) 4 (18.2) 9 (8.6)
1 (1.9) 0 (0.0) 3 (2.8)
0 (0.0) 1 (4.55) 1 (1.0)
0 (0.0) 0 (0.0) 0 (0.0)
7 (13.2) 3 (13.6) 14 (13.3)
2 (3.8) 2 (9.1) 4 (3.8)
4 (7.5) 0 (0.0) 4 (3.8)
0 (0.0) 1 (4.55) 3 (2.8)
1 (1.9) 1 (4.55) 2 (1.9)
0 (0.0) 0 (0.0) 1 (1.0)
1 (1.9) 0 (0.0) 1 (1.0)
0 (0.0) 1 (4.55) 1 (1.0)
38 (71.7) 14 (63.3) 75 (71.4)
38 (71.7) 14 (63.3) 75 (71.4)
51 (96.2) 19 (86.4) 97 (92.4)
.
19F, and 23F.
, 18C, 19A, 19F, and 23F.
Table 4 Laboratory findings of hospitalized children with invasive pneumococcal disease from 1998 to 2010 according to PCV7
and non-PCV7 serotypes.
PCV7 serotypes (n Z 72) Non-PCV7 serotypes (n Z 29) p
WBC cells/mm3 17,336  10,045 15,617  10,256 0.453
WBC <4500 cells/mm3 10 (13.9) 7 (24.1) 0.245
WBC >20,000 cells/mm3 28 (38.9) 9 (31.0) 0.502
Presence of immature PMN 24 (33.3) 12 (41.3) 0.253
Platelets (103 cells/mm3) 330  153 305  220 0.178
Platelets <150  103 cells/mm3 11 (15.3) 4 (13.8) 0.413
CRP (mg/L) 150.2  119.6 212.0  124.4 0.025
CRP >200 mg/L 23 (31.9) 15 (51.7) 0.073
Penicillin sensitivity n Z 75 n Z 30
Non-meningitis 75 (100.0) 29 (96.7) 0.286
Meningitis 13 (17.3) 16 (53.3) <0.005
Ceftriaxone sensitivity
Non-meningitis 73 (97.3) 27 (90.0) 0.139
Meningitis 42 (56.0) 23 (76.7) 0.074
Data are presented as n (%) or mean  SD.
CRP Z C-reactive protein; PCV7 Z 7-valent pneumococcal vaccine; PMN Z polymorphonuclear leukocytes; WBC Z white blood cell.
566 C.-F. Shen et al.unvaccinated children through the reduction of nasopha-
ryngeal carriage of pneumococci in the PCV7 vaccinee. This
indirect effect had been observed in adults after the uni-
versal vaccination of children with PCV7 in Alaska.26 Millar
et al27 also demonstrated that vaccine-type pneumococcal
carriage was lower among adults and unvaccinated children
living with a PCV7 vaccine. This herd effect may result from
reduced nasopharyngeal carriage and transmission.
Four cases of serotype 19A IPD in this study presented
with complicated pneumonia. One case occurred in 2000
and was susceptible to both penicillin and ceftriaxone.
However, three cases that occurred after 2008 all had a
higher MIC to penicillin and ceftriaxone. Serotype 19A may
have existed prior to the widespread use of PCV7. How-
ever, it was noticed to be an important emerging serotype
4 years after universal PCV7 vaccination in the United
States.28 Later, the increase in serotype 19A was noted in
other countries with widespread use of PCV7.29,30 By
contrast, the emergence of serotype 19A is noted after
the introduction of PCV7. In Taiwan, a marked increase of
serotype 19A from 2000-2005 to 2006-2008 (11.5%) was
found in the study conducted by Liao et al.25 TheTable 5 Pulmonary complications among hospitalized children
Serotypes Complicated
pneumonia
(n Z 31)
Un
lob
(n
PCV7 6B 4 (12.9) 4 (
9V 2 (6.5) 0 (
14 10 (32.3) 6 (
23F 0 (0.0) 3 (
Non-PCV7 3 11 (35.5) 1 (
6A 0 (0.0) 1 (
19A 4 (12.9) 0 (
23A/B 0 (0.0) 2 (
Data are presented as n (%).
OR Z odds ratio; PCV7 Z 7-valent pneumococcal vaccine.explanation for this emergence replacement may result
from the expansion of previous minority strains, replace-
ment of PCV7 with nonvaccine strains, or capsular switch
driven by vaccine selective pressure.6 However, even
under universal vaccination with PCV7, the highest rates
of serotype 19A were found in countries with the greatest
antibiotic use, whereas countries with low rates of anti-
biotic resistance have a relatively stable incidence of
serotype 19A-related disease.6 As PCV7 has not been
included in routine vaccination programs in Taiwan, the
increase of serotype 19A IPDs might be due to the
expansion of previous minority strains under antibiotic
pressure.
In summary, since the introduction of immunization with
PCV7 in Taiwan in 2005, the rates of IPD in young children
have markedly decreased. However, IPDs from non-PCV7
serotypes, predominantly serotypes 3 and 19A, have
increased.31 The evidence for serotype replacement within
IPDs after the introduction of PCV7 is undeniable.10,32,33 In
this study, among the seven fatal cases with known sero-
types in children, four (57.1%) were caused by serotypes
contained in PCV7 and six (85.7%) with serotypes containedwith pneumococcal pneumonia by serotype.
complicated
ar pneumonia
Z 17)
p OR (95% CI)
23.5) 0.429 0.4815 (0.104 e 2.23)
0.0) 0.533 e
35.3) 1.000 0.873 (0.251 e 3.041)
17.6) 0.039 e
5.9) 0.035 8.8 (1.024 e 75.59)
5.9) 0.354 e
0.0) 0.282 e
11.8) 0.121 e
Serotype manifestations of invasive pneumococcal disease 567in PCV13. PCV13 contains the seven serotypes in PCV7 plus
six additional serotypes (serotypes 1, 3, 5, 6A, 7F, and 19A).
The use of PCV13 in the routine immunization schedule has
the potential to further reduce the mortality and morbidity
associated with IPDs.34Acknowledgments
The authors thank Dr. Yu-Chia Hsieh for providing help on
serotype identification. This study was supported in part by
grants from the National Science Council, Taiwan (96-2314-
B-006-030-MY3 and 99-2314-B-006-015-MY3).References
1. American Academy of Pediatrics., Committee on Infectious
Diseases. Policy statement: recommendations for the preven-
tion of pneumococcal infections, including the use of pneu-
mococcal conjugate vaccine (Prevnar), pneumococcal
polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics
2000;106:362e6.
2. Preventing pneumococcal disease among infants and young
children. Recommendations of the Advisory Committee on
Immunization Practices (ACIP). MMWR Recomm Rep 2000;49:
1e35.
3. Invasive pneumococcal disease in children 5 years after con-
jugate vaccine introductioneeight states, 1998-2005. MMWR
Morb Mortal Wkly Rep 2008;57:144e8.
4. Direct and indirect effects of routine vaccination of children
with 7-valent pneumococcal conjugate vaccine on incidence of
invasive pneumococcal diseaseeUnited States, 1998e2003.
MMWR Morb Mortal Wkly Rep 2005;54:893e7.
5. Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive
pneumococcal disease and serotype distribution among
Streptococcus pneumoniae isolates in young children in
Europe: impact of the 7-valent pneumococcal conjugate vac-
cine and considerations for future conjugate vaccines. Int J
Infect Dis 2010;14:e197e209.
6. Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused
by serotype 19A: review of the literature and implications for
future vaccine development. Vaccine 2010;28:4249e59.
7. Gonzalez BE, Hulten KG, Lamberth L, Kaplan SL, Mason Jr EO.
Streptococcus pneumoniae serogroups 15 and 33: an increasing
cause of pneumococcal infections in children in the United
States after the introduction of the pneumococcal 7-valent
conjugate vaccine. Pediatr Infect Dis J 2006;25:301e5.
8. Byington CL, Samore MH, Stoddard GJ, Barlow S, Daly J,
Korgenski K, et al. Temporal trends of invasive disease due to
Streptococcus pneumoniae among children in the intermoun-
tain west: emergence of nonvaccine serogroups. Clin Infect Dis
2005;41:21e9.
9. Byington CL, Korgenski K, Daly J, Ampoto K, Pavia A, Mason EO,
et al. Impact of the pneumococcal conjugate vaccine on
pneumococcal parapneumonic empyema. Pediatr Infect Dis J
2006;25:250e4.
10. Hsieh YC, Lin PY, Chiu CH, Huang YC, Chang KY, Liao CH, et al.
National survey of invasive pneumococcal diseases in Taiwan
under partial PCV7 vaccination in 2007: Emergence of serotype
19A with high invasive potential. Vaccine 2009;27:5513e8.
11. Huang YC, Ho YH, Hsieh YC, Lin HC, Hwang KP, Chang LY, et al.
A 6-year retrospective epidemiology study of pediatric pneu-
mococcal pneumonia in Taiwan. J Formos Med Assoc 2008;12:
945e51.12. Chen YY, Yao SM, Chou CY, Chang YC, Shen PW, Huang CT, et al.
Surveillance of invasive Streptococcus pneumoniae in Taiwan,
2002e2003. J Med Microbiol 2006;55:1109e14.
13. Lin WJ, Lo WT, Chou CY, Chen YY, Tsai SY, Chu ML, et al.
Antimicrobial resistance patterns and serotype distribution of
invasive Streptococcus pneumoniae isolates from children in
Taiwan from 1999 to 2004. Diagn Microbiol Infect Dis 2006;56:
189e96.
14. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM,
Lynfield R, et al. Decline in invasive pneumococcal disease
after the introduction of protein-polysaccharide conjugate
vaccine. N Engl J Med 2003;348:1737e46.
15. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T,
Hurlburt DA, et al. Invasive pneumococcal disease caused by
nonvaccine serotypes among Alaska native children with high
levels of 7-valent pneumococcal conjugate vaccine coverage.
JAMA 2007;297:1784e92.
16. Bender JM, Ampofo K, Korgenski K, Daly J, Pavia AT, Mason EO,
et al. Pneumococcal necrotizing pneumonia in Utah: Does
serotype matter? Clin Infect Dis 2008;46:1346e52.
17. Fletcher M, Leeming J, Cartwright K, Finn A. Childhood em-
pyema: limited potential impact of 7-valent pneumococcal
conjugate vaccine. Pediatr Infect Dis J 2006;25:559e60.
18. Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H,
Arsene JP, et al. Immunogenicity of the 10-valent pneumo-
coccal non-typeable Haemophilus influenzae protein D conju-
gate vaccine (PHiD-CV) compared to the licensed 7vCRM
vaccine. Pediatr Infect Dis J 2009;28(Suppl 4):S66e76.
19. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV,
Facklam RR. Pneumococcal polysaccharide vaccine efficacy.
An evaluation of current recommendations. JAMA 1993;270:
1826e31.
20. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR,
et al. Efficacy, safety and immunogenicity of heptavalent
pneumococcal conjugate vaccine in children. Northern Cali-
fornia Kaiser Permanente Vaccine Study Center Group. Pediatr
Infect Dis J 2000;19:187e95.
21. O’Brien KL, Moulton LH, Reid R, Weatherholtz R, Oski J,
Brown L, et al. Efficacy and safety of seven-valent conjugate
pneumococcal vaccine in American Indian children: group
randomised trial. Lancet 2003;362:355e61.
22. Shinefield HR, Black S, Ray P, Chang I, Lewis N, Fireman B,
et al. Safety and immunogenicity of heptavalent pneumo-
coccal CRM197 conjugate vaccine in infants and toddlers.
Pediatr Infect Dis J 1999;18:757e63.
23. Ghaffar F, Barton T, Lozano J, Muniz LS, Hicks P, Gan V,
et al. Effect of the 7-valent pneumococcal conjugate vaccine
on nasopharyngeal colonization by Streptococcus pneumo-
niae in the first 2 years of life. Clin Infect Dis 2004;39:
930e8.
24. Updated recommendation from the Advisory Committee on
Immunization Practices (ACIP) for use of 7-valent pneumo-
coccal conjugate vaccine (PCV7) in children aged 24-59 months
who are not completely vaccinated. MMWR Morb Mortal Wkly
Rep 2008;57:343e4.
25. LiaoWH, Lin SH, Lai CC, Tan CK, Liao CH, Huang YT, et al. Impact
of pneumococcal vaccines on invasive pneumococcal disease in
Taiwan. Eur J Clin Microbiol Infect Dis 2010;29:489e92.
26. Hennessy TW, Singleton RJ, Bulkow LR, Bruden DL,
Hurlburt DA, Parks D, et al. Impact of heptavalent pneu-
mococcal conjugate vaccine on invasive disease, antimicro-
bial resistance and colonization in Alaska natives: progress
towards elimination of a health disparity. Vaccine 2005;23:
5464e73.
27. Millar EV, Watt JP, Bronsdon MA, Dllas J, Reid J, Santosham M,
et al. Indirect effect of 7-valent pneumococcal conjugate
vaccine on pneumococcal colonization among unvaccinated
household members. Clin Infect Dis 2008;47:989e96.
568 C.-F. Shen et al.28. Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W,
Craig AS, et al. Incidence of pneumococcal disease due to non-
pneumococcal conjugate vaccine (PCV7) serotypes in the
United States during the era of widespread PCV7 vaccination,
1998e2004. J Infect Dis 2007;196:1346e54.
29. Munoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-
Garcia JJ, Pallares R. Emergence of invasive pneumococcal
disease caused by nonvaccine serotypes in the era of 7-valent
conjugate vaccine. Clin Infect Dis 2008;46:174e82.
30. Roc He PW, Krause V, Cook H, Barralet J, Coleman D,
Sweeny A, et al. Invasive pneumococcal disease in Australia,
2006. Commun Dis Intell 2008;32:18e30.
31. Lu CY, Huang LM. How many is enough? Will conjugated
pneumococcal vaccines with more serotypes and fewer doses
work better? J Formos Med Assoc 2011;110:67e9.32. Salleras L, Dominguez A, Ciruela P, Izquierdo C, Navas E,
Torner N, et al. Changes in serotypes causing invasive
pneumococcal disease (2005e2007 vs. 1997e1999) in chil-
dren under 2 years of age in a population with intermediate
coverage of the 7-valent pneumococcal conjugated vaccine.
Clin Microbiol Infect 2009;15:997e1001.
33. Aguiar SI, Serrano I, Pinto FR, Melo-Cristino J, Ramirez M.
Changes in Streptococcus pneumoniae serotypes causing inva-
sive disease with non-universal vaccination coverage of the
seven-valent conjugate vaccine. Clin Microbiol Infect 2008;14:
835e43.
34. Wu PS, Huang LM, Chang IS, Lu CY, Shao PL, Tsai FY, et al. The
epidemiology of hospitalized children with pneumo-
coccal/lobar pneumonia and empyema from 1997 to 2004 in
Taiwan. Eur J Pediatr 2010;169:861e6.
